The effect of latanoprost on XXXX : a preliminary comparative study.

@entity1 @entity75 @entity840 @entity726 @entity1694 @entity2118 @entity3774
UNASSIGNED: Latanoprost (LT), a @entity3774 (PGF2a ) analogue used in the treatment of @entity726 , was found to induce @entity2118 in @entity840 in addition to its known periocular and iridal pigmentation side effects. This study aims to evaluate the efficacy of topical LT in the induction of skin repigmentation in @entity1 with @entity1694 and to compare its potency with narrow band ultraviolet (UV) B (NB-UVB). The result of their combination was also assessed. This study involved 22 @entity1 with bilateral and symmetrical @entity75 , stable for the last three months, divided into three groups: group I, to evaluate LT vs. placebo; group II, to evaluate LT vs. NB-UVB; and group III, to evaluate the effect of their combination. The response to treatment was evaluated by taking photographic records of the treated lesions with follow-up photography every two weeks. After three months, assessment of the degree and extent of repigmentation was performed. Follow-up assessment was done six months after termination of the trial for the persistence of pigmentation, recurrence, or development of any side effects. LT was found to be better than placebo and comparable with the NB-UVB in inducing skin repigmentation. This effect was enhanced by the addition of NB-UVB. LT could be a promising treatment for @entity1694 , especially the periocular variant. Its effect on skin repigmentation could be enhanced by NB-UVB exposure.
